Importantly, combining SRSF1 inactivation in tumor cells with PD-1 blockade significantly improved survival in B16F10 melanoma, Hep1-6 subcutaneous tumors, and CTNNB1N90; Trp53KO autochthonous murine HCC models. This evidence concerns the gene SRSF1 and hepatocellular carcinoma.